SRC and malignant colon neoplasm: While direct evidence of RNT inhibiting the c-Src/Pyk2 signaling pathway is currently lacking, noteworthy insights emerge from the chemoprotective effects of its derivative, isorhamnetin, observed in colon cancer [46].